TMCnet News
Research and Markets: Astellas Pharma's Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023Research and Markets (http://www.researchandmarkets.com/research/phrg4s/irribow) has announced the addition of the "Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering. Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indiated for the treatment of the disorder, and it is also characterized by significant unmet needs. Irribow (ramosetron) is a product that was developed and is marketed by Astellas Pharma, and is available only in Japan for the treatment of males with IBS-D. In July 2014, Astellas announced that it had submitted an sNDA for Irribow for the treatment of females with IBS-D to the Ministry of Health, Labor and Welfare (MHLW) in Japan (Astellas Pharma, press release, July 14, 2014). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Classification 3.3 Symptoms 3.5 Quality of Life 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 4.1.3 Clinical Practice 5 Competitive Assessment 6 Irribow (ramosetron) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix For more information visit http://www.researchandmarkets.com/research/phrg4s/irribow
|
